Case Report
Copyright ©The Author(s) 2021.
World J Clin Cases. Jun 26, 2021; 9(18): 4789-4796
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4789
Figure 1
Figure 1 Colonoscopy showing a lesion located in the rectum 6 cm proximal to the anal verge.
Figure 2
Figure 2 In low-power view, the ratio of neuroendocrine carcinoma to adenocarcinoma was 3:1 (hematoxylin and eosin: 10 ×).
Figure 3
Figure 3 Two coexisting distinct histological types in separate areas and without cross-growth (hematoxylin and eosin: 100 ×).
Figure 4
Figure 4 Immunohistochemical staining of cytokeratin, chromogranin A, synaptophysin, and CD56, β-Catenin and CK20. A: Adenocarcinoma cells were strongly positive for cytokeratin (CK), while neuroendocrine carcinoma cells were weakly positive [immunohistochemistry (IHC) 200 ×]; B: Adenocarcinoma cells were negative for chromogranin A, while neuroendocrine carcinoma cells were positive (IHC 100 ×); C: Adenocarcinoma cells were negative for synaptophysin, while neuroendocrine carcinoma cells were positive (IHC 200 ×); D: Adenocarcinoma cells were negative for CD56, while neuroendocrine carcinoma cells were positive (IHC 200 ×); E: Adenocarcinoma cells were strongly positive for β-Catenin (in the cell membrane) and positive in the cell nucleus of neuroendocrine carcinoma cells (IHC 40 ×); F: Adenocarcinoma cells were strongly positive for CK20, while neuroendocrine carcinoma cells were positive (IHC 100 ×).
Figure 5
Figure 5 Immunohistochemical staining of MSH2, MSH6, PMS2, MLH1, andKi-67. A: MSH6 was positive in both adenocarcinoma and neuroendocrine carcinoma cells [immunohistochemistry (IHC) 100 ×]; B: MSH2 was positive in both adenocarcinoma and neuroendocrine carcinoma cells (IHC 40 ×); C: PMS2 was positive in both adenocarcinoma and neuroendocrine carcinoma cells (IHC 100 ×); D: MLH1 was positive in both adenocarcinoma and neuroendocrine carcinoma cells (IHC 100 ×); E: Ki-67 proliferation index was 60% in adenocarcinoma cells and 40% in neuroendocrine carcinoma cells (IHC 200 ×).
Figure 6
Figure 6 Competitive blocker quantitative polymerase chain reaction showed a KRAS (c. 34G>C) mutation.